Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for evaluating lung infection medicine

An evaluation method and technology for pulmonary infection, applied in antibacterial drugs, medical raw materials derived from bacteria, etc., can solve the problems of difficulty in identifying infectious bacteria or colonized bacteria, lack of animal models, etc., and achieve significant curative effect, strong feasibility, and operation. simple effect

Inactive Publication Date: 2009-12-23
ZHEJIANG UNIV +1
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, reports on the pathogenic mechanism of Acinetobacter baumannii are rare, and there is a very difficult problem that has been plaguing the clinic: it is difficult to distinguish whether Acinetobacter baumannii isolated from the respiratory tract is an infectious bacteria or a colonizing bacteria
[0006] 2. Current research on Acinetobacter baumannii lung infection lacks an ideal animal model
[0009] In view of the high incidence of clinical Acinetobacter baumannii lung infection and the lack of animal models for experimental research, at present, it is urgent to establish a stable and controllable, simple and practical, economical and convenient, good operability and high repeatability of Baumann's insufficiency Animal model of Acinetobacter lung infection to solve the problem of differential diagnosis between colonization and infection, and successfully carry out research on the pathogenic mechanism and treatment methods of imipenem-resistant Acinetobacter baumannii lung infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for evaluating lung infection medicine
  • Method for evaluating lung infection medicine
  • Method for evaluating lung infection medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] 1. Materials

[0032] 1.1 Source of strain: The imipenem-resistant Acinetobacter baumannii used in the experiment was isolated from sputum samples from the First Affiliated Hospital of Zhejiang University School of Medicine, and identified by WITEK-II and OXA-51-like gene sequencing.

[0033] 1.2. Culture medium: blood plate, produced by Mérieux, France; M-H agar, produced by Columbia.

[0034] 1.3 Experimental drug: methotrexate for injection: produced by Jiangsu Hengrui Medicine Co., Ltd., batch number: 07072812;

[0035] 1.4. Experimental animals: SPF grade BALB / C mice, aged 4-5 weeks, weighing 13-14g, male, purchased from Zhejiang Experimental Animal Center, certificate number: SCXK (Zhejiang) 2003-0001.

[0036]1.5. Instruments and equipment: ultrasonic nebulizer, Jiangsu Yuyue Medical Instrument Co., Ltd., VITEK-AMS automatic microbial analyzer. SW-II-A / B 3 Biological safety cabinet: Shanghai Shangjing Purification Equipment Co., Ltd. Atomized plastic barrels ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a method for evaluating a lung infection medicine. In the method, an acinetobacter baumannii lung infection model is constructed by an ultrasonic atomization method, bacterium quantitative culture and pathological inspection are carried out, and comprehensive evaluation is carried out according to various indexes, such as general situations, pathological changes, lung bacterium number changes and the like, of rats at different infection time. The method for evaluating the medicine, which is provided by the invention, has the advantages of strong practicability, very high repeatability, reliability, applicability and controllability of the model, very small difference between model rats, good stability of the model, high similarity degree with a clinical pathogenic process, high model formation speed and the like, has the most pivotal advantage of simple operation of the model constructed by the method, can carry out batch operation simultaneously and provides a basis for researching on acinetobacter baumannii lung infection pathogenic mechanism and sieving treating medicines.

Description

technical field [0001] The invention belongs to drug evaluation, and relates to a drug evaluation method for pulmonary infection, in particular to a method for evaluating drug for Acinetobacter baumannii pulmonary infection. Background technique [0002] 1. The positive rate of sputum culture of Acinetobacter baumannii is high, and it is difficult to distinguish infection from colonization [0003] Bacterial infectious diseases are still common diseases in my country, and the proportion of infections caused by opportunistic pathogens is increasing, which seriously threatens human health. Acinetobacter baumannii is an important opportunistic pathogen in hospital infection. In recent years, Acinetobacter baumannii infection has been increasing day by day, and its drug resistance has been increasing, which has brought great difficulties to clinical treatment, and has attracted great attention from clinicians and microbiologists. In particular, during the military operations o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/74A61P31/04
Inventor 俞云松余道军
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products